Laboratory of Genetic Diagnostic

Can geneticists help oncologists?

Not only hereditary diseases are determined using genetic research, during treatment of oncological patients we perform gene mutation researches, which are important during application of biological targeted therapy. It is a part of an individualised treatment, the possibility to choose the most suitable medicine for treatment of the patient.

The newest genetic analysis methods: a next generation sequencing and real-time PCR. Next-Generation Sequencing allows to perform multiple gene sequencing during one run and to determine the overall gene mutation or gene expression profile. Real-time PCR method allows detecting selected gene mutations precisely, sensitively and rapidly, it is important for the selection of targeted therapies and for predicting of the course of the disease. Cancer DNA and cancer cells, circulating in body fluids, are examined in the laboratory. Researches of BRCA1/2 and other gene mutations, which help to diagnose familial tumors, are performed. Over 40 thousand immunoassay tests are performed in the laboratory of tumor markers every year; the wide spectrum of examined tumor markers is implemented.

Performed research directions are related to search and detection of non-invasive biomarkers.

  1. LMT SEN 09/2016 “Molecular tools for individualisation of long-term monitoring and treatment of prostate cancer.”
  2. Study of kidney cancer molecular markers in patients' urine (ordered research of “Novartis Pharma Services”, sponsored by MITA).


  1. Daniunaite K, Bakavicius AZukauskaite K, Rauluseviciute I, Lazutka JR, Ulys A, Jankevicius F, Jarmalaite S. Promoter Methylation of PRKCB, ADAMTS12, and NAALAD2 Is Specific to Prostate Cancer and Predicts Biochemical Disease Recurrence. Int J Mol Sci. 2021; 22(11):6091. doi: 10.3390/ijms22116091. (IF=5,923)
  2. Horvath A, Bausys A, Sabaliauskaite R, Stratilatovas E, Jarmalaite S, Schuetz B, Stiegler P, Bausys R, Stadlbauer V, Strupas K. Distal Gastrectomy With Billroth II Reconstruction Is Associated With Oralization of Gut Microbiome and Intestinal Inflammation: A Proof-of-Concept Study. Ann Surg Oncol. 2021; Volume 28, Issue 2, Pages 1198-1208. (IF=4,061)
  3. Kubiliute R, Januskeviciene I, Urbanaviciute R, Daniunaite K, Drobniene M,  Ostapenko V, Daugelavicius R, Jarmalaite S. Nongenotoxic ABCB1 activator tetraphenylphosphonium can contribute to doxorubicin resistance in MX-1 breast cancer cell line. Sci Rep. 2021; 11(1):6556:1-11. doi: 10.1038/s41598-021-86120-6. (IF=3,998)
  4. Kubiliūtė R, Jarmalaitė S. Epigenetic Biomarkers of Renal Cell Carcinoma for Liquid Biopsy Tests. Int. J. Mol. Sci. 2021, 22(16): 8846:1-24. doi: 10.3390/ijms22168846 (IF=5,923)
  5. Punceviciene E, Rovas A, Puriene A, Stuopelyte K, Vitkus D, Jarmalaite S, Butrimiene I. Investigating the relationship between the severity of periodontitis and rheumatoid arthritis: a cross-sectional study. Clin Rheumatol. 2021; 1-8. doi: 10.1007/s10067-021-05661-3. Online ahead of print. (IF=2,349)
  6. Punceviciene E, Gaizevska JSabaliauskaite R, Venceviciene L, Puriene A, Vitkus D, Jarmalaite S, Butrimiene I. Vitamin D and VDR Gene Polymorphisms’ Association with Rheumatoid Arthritis in Lithuanian Population. Medicina 2021, 57(4), 346:1-12. (IF=1,205)
  7. Rovas A, Puriene A, Snipaitiene K, Punceviciene E, Buragaite-Staponkiene B, Matuleviciute R, Butrimiene I, Jarmalaite S. Analysis of periodontitis-associated miRNAs in gingival tissue, gingival crevicular fluid, saliva and blood plasma. Arch Oral Biol. 2021; 126:105125: 1-9. doi: 10.1016/j.archoralbio.2021.105125. PMID: 33862403 (IF=1,931)
  8. Rovas A, Puriene A, Punceviciene E, Butrimiene I, Stuopelyte K, Jarmalaite S. Associations of periodontal status in periodontitis and rheumatoid arthritis patients. J Periodontal Implant Sci. 2021; 51(2):124-134. doi: 10.5051/jpis.2006060303. PMID: 33913635 (IF=1,847)
  9. Žilovič D, Čiurlienė R, Sabaliauskaitė R, Jarmalaitė S. Future screening prospectives for ovarian cancer. Cancers. 2021; 13(15): 3840: 1-17; (IF=6,126)


  1. Daniunaite K, Sestokaite A, Kubiliute R, Stuopelyte K, Kettunen E, Husgafvel-Pursiainen K,  Jarmalaite S. Frequent DNA methylation changes in cancerous and noncancerous lung tissues from smokers with non-small cell lung cancer.  Mutagenesis. 2020; geaa022:1-7. (IF=3,379)
  2. Stuopelyte K, Sabaliauskaite R, Bakavicius A, Haflidadóttir BS, Visakorpi T, Väänänen RM, Patel C, Danila DC, Lilja H, Lazutka JR, Ulys A, Jankevicius F, Jarmalaite S. Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. J Urol. 2020; 204(1):71-78 . (IF=5,925)
  3. Bakavičius A, Drevinskaitė M, Daniūnaitė K, Barisienė M, Jarmalaitė S, Jankevičius F.The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival. Medicina (Kaunas). 2020; 56(2):1-11. (IF=1,205)
  4. Sadzevičienė I, Liaugaudienė O, Besusparis J, Asadauskienė J, Kulikienė I, Brasiūnienė B, Sabaliauskaitė R, Jarmalaitė S. Recurrent Germline BRCA2 Gene Mutation in Lithuanian Family. Medicina 2020, 56(3), 119:1-9; doi: 10.3390/medicina56030119 (IF=1,205)


  1. Bakavicius A, Daniunaite K, Zukauskaite K, Barisiene M, Jarmalaite S, Jankevicius F. Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging. Clin Epigenetics. 2019 Aug 5;11(1):115. doi: 10.1186/s13148-019-0716-z. (IF=5,496)
  2. Maleckaite R, Zalimas A, Bakavicius A, Jankevicius F, Jarmalaite S, Daniunaite K. DNA methylation of metallothionein genes is associated with the clinical features of renal cell carcinoma. Oncol Rep. 2019 Jun;41(6):3535-3544. doi: 10.3892/or.2019.7109. (IF=3,041)


  1. Demidenko R, Daniunaite K, Bakavicius A, Sabaliauskaite RSkeberdyte A, Petroska D, Laurinavicius A, Jankevicius F, Lazutka JR, Jarmalaite S. Decreased expression of MT1E is a potential biomarker of prostate cancer progression. Oncotarget. 2017 Jun 27;8(37):61709-61718. doi: 10.18632/oncotarget.18683. (IF=5,168)
  2. Gyvyte U, Juzenas S, Salteniene V, Kupcinskas J, Poskiene L, Kucinskas L, Jarmalaite S, Stuopelyte K, Hemmrich-Stanisak G, Hübenthal M, Franke A, Pangonyte D, Lesauskaite V, Kupcinskas L, Skieceviciene J. MiRNA profiling of gastrointestinal stromal tumors by next-generation sequencing. Oncotarget. 2017 Jun 6;8(23):37225-37238. doi: 10.18632/oncotarget.16664. (IF=5,168)
  3. Kettunen E, Hernandez-Vargas H, Cros MP, Durand G, Le Calvez-Kelm F, Stuopelytė K, Jarmalaitė S, Salmenkivi K, Anttila S, Wolff H, Herceg Z, Husgafvel-Pursiainen K. Asbestos-associated genome-wide DNA methylation changes in lung cancer. Int J Cancer. 2017 Nov 15;141(10):2014-2029. doi: 10.1002/ijc.30897. (IF=6,513)


  1. Stuopelyte KDaniunaite K, Bakavicius A, Lazutka JR, Jankevicius F, Jarmalaite S. The utility of urine-circulating miRNAs for detection of prostate cancer. Br J Cancer. 2016 Sep 6;115(6):707-15. doi: 10.1038/bjc.2016.233. (IF=6,176)
  2. Kubiliūtė R, Šulskytė I, Daniūnaitė K, Daugelavičius R, Jarmalaitė S. Molecular features of doxorubicin-resistance development in colorectal cancer CX-1 cell line. Medicina (Kaunas). 2016;52(5):298-306. doi: 10.1016/j.medici.2016.09.003. (IF=0,802)
  3. Stuopelytė KDaniūnaitė K, Jankevičius F, Jarmalaitė S. Detection of miRNAs in urine of prostate cancer patients. Medicina (Kaunas). 2016;52(2):116-24. doi: 10.1016/j.medici.2016.02.007. (IF=0,802)

Updated 2021-09-23 12:55